Side-by-side · Research reference
LiraglutidevsSermorelin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedVerified14/45 cited
BPhase 3Reviewed14/43 cited
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
Sermorelin
GHRH 1-29 fragment · Short-acting
SQ · Pre-sleep · 1×/day
01Mechanism of Action
Parameter
Liraglutide
Sermorelin
Primary target
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Pituitary GHRH receptorWalker 1994
Pathway
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisWalker 1994
Downstream effect
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Pulsatile GH release; subsequent IGF-1 elevationMolteno 2013
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
Yes — short pulse preserves feedback
Origin
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Unmodified active 29-AA fragment of human GHRH (1-44)Walker 1994
Antibody development
—
—
02Dosage Protocols
Parameter
Liraglutide
Sermorelin
Standard dose (weight, Saxenda)
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
—
Frequency
Once daily, same time each day
Once daily, pre-sleep
Titration schedule
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Phase 3 (Geref pediatric); clinical practiceWalker 1994Molteno 2013
Duration
Indefinite for chronic indication
8–12 weeks per cycle
Reconstitution
Pre-filled commercial pen (no reconstitution)
Bacteriostatic water
Timing
Any time of day; consistent
Pre-sleep, fasted preferred
Half-life
~12 min (plasma)Molteno 2013
Shorter than tesamorelin (~26 min) — simpler GHRH analogue.
Lower / starter dose
—
100 mcg per dose
04Side Effects & Safety
Parameter
Liraglutide
Sermorelin
GI symptoms
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
—
Pancreatitis risk
Rare; discontinue if suspected
—
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
—
Hypoglycemia
Low risk as monotherapy; elevated with sulfonylureas / insulin
—
Heart rate
Modest ↑ resting HR (~2-3 bpm)
—
Pregnancy / OB
Contraindicated
Avoid
Injection site reaction
—
Mild erythema, transient pain
Flushing / headache
—
Common transient effect
IGF-1 elevation
—
Modest at standard doses
Cancer risk
—
Contraindicated in active malignancy (GH/IGF-1 axis)
Glucose handling
—
Generally neutral
Absolute Contraindications
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
Sermorelin
- ·Active malignancy
- ·Pregnancy / breastfeeding
- ·Disrupted hypothalamic-pituitary axis
Relative Contraindications
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
Sermorelin
- ·Untreated diabetes
05Administration Protocol
Parameter
Liraglutide
Sermorelin
1. Reconstitution / device
Commercial pre-filled pen, no reconstitution required.
Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites.
SQ — abdomen or thigh. Rotate sites.
3. Timing
Once daily, same time each day. Take with or without food.
Pre-sleep, fasted.
4. Storage
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
5. Needle
Pen-supplied 32G needle.
29–31G, 4–8 mm insulin syringe.
06Stack Synergy
Liraglutide
— no documented stacks
Sermorelin
+ Ipamorelin
StrongSermorelin (GHRH analogue) and ipamorelin (selective GHRP) form the prototypical GHRH+GHRP dual-axis stack at the lowest cost. Both peak within 30 min and produce a sharp physiological GH pulse without cortisol/prolactin elevation.
- Sermorelin
- 200–300 mcg SQ · pre-sleep
- Ipamorelin
- 200–300 mcg SQ · same injection
- Primary benefit
- Pulsatile GH stimulation, recovery, body composition